Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00232102 · ClinicalTrials.gov registry record · Phase 3
Extension Study to Assess the Long-Term Safety of Tegaserod in Women With Symptoms of Dyspepsia
A Phase 3 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 423
- Enrollment target
NCT00232102 is a Phase 3 study that has completed, run by Novartis. The registered enrollment target is 423 participants.
The verdict
NCT00232102, a Phase 3 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 423 participants
- Enrollment target
Study Summary
This study is being done to evaluate the long-term safety of tegaserod in women with symptoms of dyspepsia who have completed the core study. Tegaserod will be evaluated at 6 mg twice daily.
Interventions
- DRUG Tegaserod
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 423 participants |
| Start Date | 2004-09 |
| Est. Completion | 2006-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00232102
The ClinicalTrials.gov registry entry for NCT00232102 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 423 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tegaserod is the first listed.
NCT00232102 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00232102 about?
NCT00232102 is a clinical study titled "Extension Study to Assess the Long-Term Safety of Tegaserod in Women With Symptoms of Dyspepsia". This study is being done to evaluate the long-term safety of tegaserod in women with symptoms of dyspepsia who have completed the core study. Tegaserod will be evaluated at 6 mg twice daily.
What is the current status of trial NCT00232102?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 423 participants. The study started on 2004-09. Estimated completion is 2006-08.
What interventions are being tested in trial NCT00232102?
The interventions under investigation include: Tegaserod (DRUG).
Who is sponsoring clinical trial NCT00232102?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.